AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Financial Statements
- Click here to download Abbvie Inc's Income Statement
- Click here to download Abbvie Inc's Balance Sheet
- Click here to download Abbvie Inc's Statement of Cash Flows
Key Info
- Industry: Pharmaceutical Preparation Manufacturing
- Sector: Manufacturing
- CEO Name: Richard Gonzalez
Key Statistics
- Stock Price: $182.1
- Dividend Yield: 3.2%
- Market Capitalization: $322,434,815,604
- Shares Outstanding: 1,770,646,983
- Number of Employees: 50,000
- Trailing 12-Month EPS: $2.72
- Trailing 12-Month DPS: $5.9
- Payout Ratio: 216.9%
Important Dates
- Next Earnings Date: 2024-04-25
- Next Ex-Dividend Date: 2024-01-12
Price Trends
- Current Stock Price: $182.1
- 52-week high: $182.89
- 52-week low: $127.03
- 200-day moving average: $157.1
- 50-day moving average: $178.11
Performance
- 1-Month Price Return: 2.3%
- 3-Month Price Return: 18.6%
- 6-Month Price Return: 24.6%
- 1-Year Price Return: 20.0%
- 2-Year Price Return: 20.1%
- 5-Year Price Return: 184.6%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast